The global healthcare industry, a sector fundamentally dedicated to the preservation of human life, is increasingly under scrutiny for its substantial environmental cost. While life-saving innovations continue to advance, the machinery required to produce them—pharmaceutical and biotechnology supply chains—has become a significant contributor to the climate crisis. Despite a wave of ambitious, high-profile sustainability pledges from industry giants, the data reveals a troubling reality: total carbon emissions from the sector continue to climb, driven by soaring production demands and the complexities of global supply chains.
Main Facts: The Environmental Cost of Modern Medicine
The healthcare industry is responsible for an estimated 4.4% of total annual global greenhouse gas (GHG) emissions. Within this footprint, the pharmaceutical and biotechnology sectors are critical components, accounting for approximately 71% of the total healthcare supply chain impact.
The manufacturing of medicine is inherently resource-intensive. Industry standards suggest that for every single kilogram of an active pharmaceutical ingredient (API) produced, between 25 and 100 kilograms of chemical waste are generated. A significant culprit in this environmental toll is the heavy reliance on solvents, which represent 80% to 90% of the total mass in pharmaceutical manufacturing processes. This inefficiency is reflected in the Process Mass Intensity (PMI)—a measure of chemical waste per unit of product. With a median PMI ranging from 168 to 308, the pharmaceutical sector remains significantly more carbon-intensive than many other chemical manufacturing industries.
Beyond direct carbon output, the industry faces an ecological challenge regarding pharmaceutical residues. These substances enter the environment via patient excretion, manufacturing plant effluent, and the improper disposal of unused medication. While current concentrations in drinking water are generally deemed low-risk for humans, the long-term impact on biodiversity remains a concern. Most alarmingly, antibiotic residues in manufacturing waste have been linked to the acceleration of antibiotic resistance, creating a potential pathway for the development of "superbugs" that could undermine global public health.
Chronology: A Trajectory of Increasing Impact
To understand the industry’s current predicament, one must look at the timeline of its carbon output:
- 2020–2021: According to the My Green Lab 2022 report, the total carbon output of public pharmaceutical companies surged by 15%, rising from 197 million tCO2e to 227 million.
- 2022: The sector’s contribution to global emissions grew from 3.9% in 2021 to 5% in 2022, signaling a rapid acceleration in carbon intensity.
- 2024: Industry alignment with the 1.5°C climate trajectory—a key benchmark of the Paris Agreement—stood at 30%.
- 2025: The My Green Lab 2025 Carbon Impact Report noted an improvement in alignment, reaching 52%. However, this progress in goal-setting was undercut by data showing a 2% increase in absolute emissions between 2023 and 2024.
This chronology illustrates a "decoupling" failure: while companies are aligning their long-term strategies with global climate targets, their operational footprints continue to expand, suggesting that efficiency gains are being swallowed by the sheer volume of increased production.
Supporting Data: The Scope 3 Conundrum
The Greenhouse Gas (GHG) Protocol categorizes emissions into three scopes. Scopes 1 and 2 cover direct emissions from owned sources and purchased energy, respectively. Scope 3—which includes purchased goods, services, logistics, and product end-of-life—represents a staggering 82% of the industry’s total carbon footprint.
While the top 25 public pharmaceutical companies have shown success in reducing Scope 1 and 2 emissions, Scope 3 remains the primary barrier to net-zero status. For instance, AstraZeneca has made strides in operational efficiency, yet its absolute Scope 3 emissions grew by 24% compared to its 2019 baseline. Similarly, Eli Lilly reported a significant increase in Scope 3 emissions, rising from approximately 2.99 million metric tons in 2021 to 5.14 million in 2023.
This data highlights the difficulty of managing emissions that occur outside a company’s direct control. Because API synthesis and raw material sourcing are often outsourced to third-party manufacturers, pharmaceutical leaders are finding it difficult to enforce their sustainability standards across a fragmented, global supply chain.
Official Responses: Corporate Pledges vs. Reality
The industry response to these findings has been a flurry of "net-zero by the 2040s" commitments.
- AstraZeneca: The company has reported that it is on track to achieve a 98% reduction in operational emissions by 2026. Furthermore, in 2025, it successfully reduced water usage by 23% and waste production by 13%.
- Sanofi: As of 2024, Sanofi reported that it is on track to reach carbon neutrality by 2030, having already achieved a 47% reduction in emissions compared to a 2019 baseline. The company has also pledged to implement strict monitoring plans at 100% of its manufacturing sites to control pharmaceutical environmental runoff.
- Novo Nordisk: In contrast to the gains made by its peers, Novo Nordisk reported a 19% increase in total emissions between 2024 and 2025. The company attributed this rise to the aggressive acquisition of new production sites and increased energy consumption necessitated by global demand for its products.
These responses underscore the central tension: pharmaceutical companies are operating in a market where demand for medicine is non-negotiable. As companies scale up to meet medical needs, the resulting carbon footprint often contradicts their corporate ESG (Environmental, Social, and Governance) reports.
Implications: The Path Toward Sustainable Medicine
The rise in emissions within the pharmaceutical sector carries profound implications for both public health and corporate accountability. If the industry continues on its current path, it risks losing its "social license to operate," facing tighter regulation, carbon taxes, and increased scrutiny from investors who are increasingly prioritizing decarbonization.
Addressing the Supply Chain
To bridge the gap between goals and reality, the industry must transition from voluntary initiatives to structural change. This includes:
- Supplier Engagement: Companies must mandate that their suppliers—often smaller, private firms—adopt renewable energy targets. Providing technical and financial support to these suppliers is critical to curbing Scope 3 emissions.
- Logistics Overhaul: Moving away from air freight toward sea or road transport is a practical, immediate step to lower the carbon intensity of global product distribution.
- Green Chemistry: The industry must invest heavily in R&D to reduce Process Mass Intensity. By designing manufacturing processes that require fewer solvents and produce less waste at the molecular level, companies can reduce their footprint at the source.
The Ecological Outlook
The long-term health of the planet is intrinsically linked to the health of the population. The threat of antibiotic resistance caused by manufacturing effluent is a stark reminder that the pharmaceutical industry cannot treat the environment as a secondary concern. The integration of "Green Chemistry" is no longer an optional sustainability goal; it is a clinical necessity to prevent a secondary public health crisis in the coming decades.
Conclusion
The pharmaceutical industry finds itself at a critical juncture. The data is clear: while sustainability targets have become more rigorous and more widely adopted, they are currently insufficient to counteract the massive increase in production volume. The sector’s reliance on complex, outsourced supply chains makes Scope 3 emissions the "final frontier" of climate action.
To achieve true sustainability, the industry must move beyond reporting and toward radical operational transparency. It must reconcile the paradox of expanding medical access while simultaneously contracting its environmental footprint. Without a fundamental transformation in how medicines are manufactured, distributed, and disposed of, the industry’s net-zero promises may remain, at best, a noble aspiration, and at worst, a failure of stewardship for the very planet it aims to keep healthy.
About the Author
